33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: A prospective cohort study
    Meeting Abstract

    Lee, Y.; Hui, J. M. H.; Leung, C.; Tsang, C. T. W.; Hui, K.; Tang, P.; Dee, E. C.; Ng, K.; McBride, S.; Nguyen, P. L.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • STAT3 operates as a rheostat regulating sensitivity of NK cells to inflammatory cytokines
    Meeting Abstract

    Grassmann, S.; Fan, S.; Kim, R.; Beroshvili, G.; Sun, J. C. Y.
    Journal of Immunology (2023)

    Fulltext@MSK | Save
  • Synthetic dual-costimulation for TCR and TCR-like targeted cell therapies
    Meeting Abstract

    Dobrin, A.; Xie, H.; Perica, K.; Jain, N.; Sadelain, M.; Hamieh, M.
    Human Gene Therapy (2023)

    Fulltext@MSK | Save
  • Prostate cancer incidence and mortality after stop age in the Goteborg branch of ERSPC
    Meeting Abstract

    Hugosson, J.; Frånlund, M.; Godtman, R. A.; Aus, G.; Bergdahl, A. G.; Khatami, A.; Lodding, P.; Pihl, C. G.; Stranne, J.; Månsson, M.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal Augment-101 phase 2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Association between psychological distress and cardiovascular health amongst cancer survivors in the United States: Findings from nationally representative data
    Meeting Abstract

    Chan, J. S. K.; Satti, D. I.; Dee, E. C.; Sharma, G.; Virani, S. S.; Liu, T.; Tse, G.
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Association between immune checkpoint inhibitors and heart failure hospitalizations: A population-based self-controlled case series
    Meeting Abstract

    Chan, J. S. K.; Lee, T. T. L.; Chou, O. H. I.; Lee, Y. H. A.; Dee, E. C.; Ng, K.; Hui, J. M. H.; Leung, F. P.; Wong, W. T.; Liu, T.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Armstrong, A. J.; Pook, D. W.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save